"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at doxorubicin (Adriamycin) and cisplatin with or without paclitaxel (Taxol) for women with advanced womb (endometrial) cancer (EORTC 55984)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is comparing 2 different chemotherapy regimes for advanced womb cancer.
One of the treatments for women with advanced womb cancer is chemotherapy. Previous trials have shown that doxorubicin (Adriamycin) and cisplatin can work well together. This trial is trying to find out if adding another chemotherapy drug called paclitaxel (Taxol) will mean that the cancer is less likely to come back. The trial will compare these two groups of drugs
- Doxorubicin (Adriamycin) and cisplatin
- Doxorubicin (Adriamycin), cisplatin and paclitaxel (Taxol)
The researchers will also look at how the different combinations of drugs will affect quality of life.
Who can enter
You can enter this trial if you
- Have advanced womb (endometrial) cancer OR
- Have womb (endometrial) cancer that has spread to another part of your body OR
- Have womb cancer that cannot be removed with surgery
- Are well enough to have chemotherapy
- Have satisfactory blood tests
- Are at least 18 years of age
You cannot enter this trial if you
- Have a type of womb cancer called mixed mesodermal, sarcoma or uterine papillary serous carcinoma (UPSC)
- Have had radiotherapy to your
pelvisin the past
- Have had chemotherapy in the past
- Have had hormone therapy in the last 4 weeks
- Have had another cancer in the last 5 years (apart from non melanoma skin cancer or carcinoma in situ of the cervix)
- Are pregnant or breastfeeding
- Have an active infection
- Cannot tolerate high dose dexamethasone (a type of
This European trial will recruit 300 patients. The trial is randomised and there are two treatment groups. The people taking part are put into the different treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.
If you are in group 1, you will have doxorubicin (Adriamycin) and cisplatin chemotherapy. You will have these drugs, as well as anti sickness drugs, through a drip into a vein in your arm. This will take about 2 hours. You will also have fluids through your drip before and after your treatment. This is one cycle of treatment, which is repeated every 3 weeks. You will have 6 cycles in total, so your treatment will take about 3 and a half months overall.
If you are in group 2, you will have doxorubicin (Adriamycin), cisplatin and pacitaxel (Taxol) chemotherapy. You will have these drugs, as well as anti sickness drugs, through a drip into a vein in your arm. This will take about 6 hours.
Before your chemotherapy you will have a
Before you start your treatment a doctor will examine you and do various tests. These will include
You will have blood tests before each cycle of chemotherapy. The scan, chest x-ray and
After your treatment finishes, you will continue to see a doctor
- Every 3 months for the first 2 years
- Every 6 months for the next 3 years
- Every year after that
You will be examined by a doctor and some of the above tests will be repeated.
You will also fill out a questionnaire that will take about 10 minutes. This will ask how you have been feeling. It is called a ‘quality of life’ study. You complete these questionnaires before your treatment, after the 3rd cycle, 6th cycle and then every 6 months.
The most common side effects of these drugs are
How to join a clinical trial
Prof N. Reed
European Organisation for Research and Treatment of Cancer (EORTC)
NIHR Clinical Research Network: Cancer